AstraZeneca cuts 600 US sales staff

The signal here is less the headcount than the silence around it: no financial terms, no timing, and no stated rationale beyond a general workforce reduction, which leaves the scope of the restructuring unclear. For a commercial organisation, cutting field sales staff typically reflects a shift in how products are promoted rather than a single product decision, though nothing in the disclosure confirms that. The open question is whether this is an isolated adjustment or part of a broader pattern of US commercial retrenchment at the company.